回生口服液调控Wnt通路CyclinD1影响人肺腺癌细胞增殖的机制

目的：研究回生口服液调控Wnt信号传导通路细胞周期蛋白D1（CyclinD1）影响人肺腺癌细胞（LAC）增殖的机制。方法：制备高、中、低剂量（11．6g／kg，5．8g／kg，2．9g／kg）回生口服液含药血清，与人肺腺癌细胞系共同培养，MTT法检测含药血清对肺腺癌细胞的抑制率，流式细胞仪检测肺腺癌细胞周期相对分布；建立C57BL／6人肺腺癌荷瘤小鼠模型，予回生口服液高、中、低剂量治疗，免疫组化法检测小鼠移植瘤肺腺癌细胞Cyclin—D1阳性表达水平。结果：与阴性对照组比较，回生口服液高、中剂量组及顺铂组含药血清对肺腺癌细胞的生长抑制率明显增高，且干预的肺腺癌细胞G1期细胞比例明显增高，s期、G2期细胞比例明显减少（P〈0．01，P〈0．05）；回生口服液中、高剂量及顺铂（DDP）治疗组小鼠肺腺癌细胞内CyclinD1阳性表达率明显低于模型组（P〈0．01）。结论：回生口服液可明显抑制人肺腺癌细胞生长，使癌细胞停滞于细胞周期的G1期，并可明显降低肺腺癌细胞内CyclinD1的阳性表达。

Mechanism of Hui-Sheng Oral Liquid Affecting the Proliferation of LAC by Controlling CyclinD1 of Wnt Signal Pathway

Objective： To study the mechanism of Hui-sheng oral liquid affecting the proliferation of the human lung adenocar- cinoma cells （ LAC ） through controlling CyclinD1 of Wnt signal pathway. Methods ： Drug serum of high, middle and low-close Hui- sheng oral liquid （ 11.6 g/kg, 5.8 g/kg, 2. 9 g/kg） were prepared. The inhibitory rate of LAC cells was calculated by MTT, and the cell cycle was analyzed by the flow cytometry. C57BL/6 solid tumor model mice were established, treated by high, middle and low-dose Hui-sheng oral liquid （ 11.6g/kg, 5.8g/kg, 2.9g/kg） for 14 days, then their tumors were taken out and the expression of CyclinD1 were detected by the immunohistochemical assay. Results： The inhibitory rate of LAC cells intervened by middle, high-dose Hui-sheng oral liquid and DDP were apparently higher than the negative control group, cells in G1 phase increased, while cells in G2 phase and S decreased （P 〈0. 01, P 〈0.05） ; The middle, high-dose Hui-sheng oral liquid and DDP could regulate down the ex- pression of CyclinD1 in the tumor （P 〈 0. 01 ） . Conclusion： Hui-sheng oral liquid could decrease the expression of CyclinD1 of LAC in Wnt Signal Pathway and prevent their G1 period turning into S period, therefore inhibit the growth of lung cancer cells.